Clinigen Group (LON:CLIN) Stock Rating Reaffirmed by Peel Hunt

Clinigen Group (LON:CLIN)‘s stock had its “buy” rating reaffirmed by equities researchers at Peel Hunt in a research note issued to investors on Thursday, February 1st. They presently have a GBX 1,350 ($18.93) price objective on the stock. Peel Hunt’s target price points to a potential upside of 35.47% from the stock’s previous close.

CLIN has been the subject of a number of other reports. Berenberg Bank initiated coverage on shares of Clinigen Group in a research report on Wednesday, November 1st. They issued a “hold” rating and a GBX 1,200 ($16.83) price target for the company. Numis Securities restated an “add” rating and set a GBX 1,208 ($16.94) target price on shares of Clinigen Group in a research report on Wednesday, January 17th. N+1 Singer restated a “buy” rating and set a GBX 1,225 ($17.18) target price on shares of Clinigen Group in a research report on Wednesday, November 29th. Finally, Royal Bank of Canada restated an “outperform” rating and set a GBX 1,360 ($19.07) target price on shares of Clinigen Group in a research report on Tuesday, November 7th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the stock. Clinigen Group presently has a consensus rating of “Buy” and a consensus target price of GBX 1,222.17 ($17.14).

Shares of Clinigen Group (LON CLIN) opened at GBX 996.50 ($13.97) on Thursday. The stock has a market cap of $1,220.00 and a P/E ratio of 33,216.67. Clinigen Group has a 52 week low of GBX 751.50 ($10.54) and a 52 week high of GBX 1,187 ($16.64).

In related news, insider Chris Rigg sold 4,955 shares of the company’s stock in a transaction on Thursday, November 23rd. The shares were sold at an average price of GBX 1,017 ($14.26), for a total transaction of £50,392.35 ($70,656.69).

ILLEGAL ACTIVITY NOTICE: “Clinigen Group (LON:CLIN) Stock Rating Reaffirmed by Peel Hunt” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece on another site, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/12/clinigen-groups-clin-buy-rating-reiterated-at-peel-hunt.html.

Clinigen Group Company Profile

Clinigen Group plc is a United Kingdom-based pharmaceutical and services company. The Company’s principal activities include management, sale and distribution of pharmaceutical products, which have associated expiry dates. The Company operates through five segments: Clinigen Clinical Trial Services (CTS), which sources commercial medical products for use in clinical studies, including comparator drugs, adjuvant drugs and rescue therapies; Idis Managed Access (MA), which is engaged in the consultancy, development, management and implementation of managed access programs for biotechnology and pharmaceutical companies; Idis Global Access (GA), which offers ethical access to post approval and short-supply medicines; Clinigen Specialty Pharmaceuticals (SP), which manufactures and distributes its own and in-licensed specialist, hospital-only medicines around the world, and Link Healthcare, which distributes pharmaceutical products in South Africa, and the Asia and Pacific region.

Analyst Recommendations for Clinigen Group (LON:CLIN)

Receive News & Ratings for Clinigen Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply